Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Aledort

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Pathophysiology of Haemostasis and Thrombosis|July 11, 2003
Why thrombin generation? From bench to bedsideLouis M Aledort
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
Treatment of factor XI deficiencyLouis M Aledort
Seminars in Thrombosis and Hemostasis|March 31, 2012
FEIBA: a prohemostatic agentCaroline Cromwell, Louis M Aledort
American Journal of Hematology|November 30, 2005
United States' factor XI-deficiency patients need a safer treatmentLouis M Aledort, Jenny Goudemand,
American Journal of Hematology|June 2, 2005
Can managed care support hemophilia in the 21st century?Louis M Aledort, James Coates
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Advances in clotting factor treatment for congenital hemorrhagic disordersMichael D Tarantino, Louis M Aledort
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
The Mount Sinai Journal of Medicine, New York|May 26, 2005
Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategiesSebastian A Mayer, Louis M Aledort
Expert Review of Hematology|June 21, 2013
Restoring hemostasis: fibrinogen concentrate versus cryoprecipitateBrian M Elliott, Louis M Aledort
The New England Journal of Medicine|December 1, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsLouis M Aledort, Bruce M Ewenstein
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Pathophysiology of Haemostasis and Thrombosis|July 11, 2003
Why thrombin generation? From bench to bedsideLouis M Aledort
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
Treatment of factor XI deficiencyLouis M Aledort
Seminars in Thrombosis and Hemostasis|March 31, 2012
FEIBA: a prohemostatic agentCaroline Cromwell, Louis M Aledort
American Journal of Hematology|November 30, 2005
United States' factor XI-deficiency patients need a safer treatmentLouis M Aledort, Jenny Goudemand,
American Journal of Hematology|June 2, 2005
Can managed care support hemophilia in the 21st century?Louis M Aledort, James Coates
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Advances in clotting factor treatment for congenital hemorrhagic disordersMichael D Tarantino, Louis M Aledort
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
The Mount Sinai Journal of Medicine, New York|May 26, 2005
Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategiesSebastian A Mayer, Louis M Aledort
Expert Review of Hematology|June 21, 2013
Restoring hemostasis: fibrinogen concentrate versus cryoprecipitateBrian M Elliott, Louis M Aledort
The New England Journal of Medicine|December 1, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsLouis M Aledort, Bruce M Ewenstein
Pageof 4